Casopitant
Top View
- Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive Or Did Clinical Trials Fail to Detect Effects?
- A Phase 2, Multicenter, Open-Label Study of BGJ398 in Patients with Recurrent Resectable Or Unresectable Glioblastoma
- Mathew, S.J., Manji, H.K., & Charney, D.S. (2008). Novel Drugs And
- Investigation of a Role for Noradrenaline in the Neurochemical
- (12) Patent Application Publication (10) Pub. No.: US 2010/0152283 A1 Gant (43) Pub
- Neurokinin Receptors in Drug and Alcohol Addiction
- Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
- Stress-Related Neuropeptides and Addictive Behaviors: Beyond the Usual Suspects
- Zunrisa Withdrawal Assessment Report
- SCNAUSEA Appendix
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- PONV Prophylaxis Guidelines
- SIOG 2007 Herrstedt.Pdf
- (12) Patent Application Publication (10) Pub. No.: US 2010/0113431 A1 Gant Et Al
- Effect of Casopitant, a Novel NK-1 Antagonist, on the Pharmacokinetics of Dolasetron and Granisetron
- (12) Patent Application Publication (10) Pub. No.: US 2013/0045979 A1 Sanfilippo (43) Pub
- Study Protocol and Results
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances